Bronchopulmonary Dysplasia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

BPD MCID: BRN056 MIFTS: 57	Bronchopulmonary Dysplasia (BPD) Categories: Fetal diseases, Rare diseases, Respiratory diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Bronchopulmonary Dysplasia

MalaCards integrated aliases for Bronchopulmonary Dysplasia:

Name: Bronchopulmonary Dysplasia ¹⁹ ⁵⁸ ⁷⁵ ⁵³ ⁵ ³⁶ ⁶³ ⁷¹

Bpd ¹⁹ ⁵⁸

Characteristics:

Prevelance:

1-5/10000 (Europe) ⁵⁸

Age Of Onset:

Infancy,Neonatal ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Fetal diseases
Anatomical: Respiratory diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Certain conditions originating in the perinatal period

Respiratory and cardiovascular disorders specific to the perinatal period

Chronic respiratory disease originating in the perinatal period

Bronchopulmonary dysplasia originating in the perinatal period

Orphanet: ⁵⁸

Rare respiratory diseases

Developmental anomalies during embryogenesis

Sources

Summaries for Bronchopulmonary Dysplasia

PubMed Health : ⁶³ Bronchopulmonary dysplasia: Bronchopulmonary (BRONG-ko-PUL-mo-NAR-e) dysplasia (dis-PLA-ze-ah), or BPD, is a serious lung condition that affects infants. BPD mostly affects premature infants who need oxygen therapy (oxygen given through nasal prongs, a mask, or a breathing tube). Most infants who develop BPD are born more than 10 weeks before their due dates, weigh less than 2 pounds (about 1,000 grams) at birth, and have breathing problems. Infections that occur before or shortly after birth also can contribute to BPD. Some infants who have BPD may need long-term breathing support from nasal continuous positive airway pressure (NCPAP) machines or ventilators.

MalaCards based summary: Bronchopulmonary Dysplasia, also known as bpd, is related to bronchial disease and newborn respiratory distress syndrome. An important gene associated with Bronchopulmonary Dysplasia is SFTPB (Surfactant Protein B), and among its related pathways/superpathways are Innate Immune System and NF-KappaB Family Pathway. The drugs Beractant and Zinc cation have been mentioned in the context of this disorder. Affiliated tissues include Lung, and related phenotypes are emphysema and cough

GARD: ¹⁹ Bronchopulmonary dysplasia is a chronic respiratory disease that results from complications related to lung injury during the treatment of infant acute respiratory distress syndrome (see these terms) in low-birth-weight premature infants or from abnormal lung development in older infants. Clinical signs are tachypnea, tachycardia and signs of respiratory distress such as intercostal recession, grunting and nasal flaring.

Orphanet: ⁵⁸ Bronchopulmonary dysplasia is a chronic respiratory disease that results from complications related to lung injury during the treatment of infant acute respiratory distress syndrome (see these terms) in low-birth-weight premature infants or from abnormal lung development in older infants. Clinical signs are tachypnea, tachycardia and signs of respiratory distress such as intercostal recession, grunting and nasal flaring.

Wikipedia: ⁷⁵ Bronchopulmonary dysplasia (BPD; part of the spectrum of chronic lung disease of infancy) is a chronic... more...

Sources

Related Diseases for Bronchopulmonary Dysplasia

Diseases related to Bronchopulmonary Dysplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 376)

#	Related Disease	Score	Top Affiliating Genes
1	bronchial disease	31.3	SCGB1A1 RNASE3 ELANE CXCL8
2	newborn respiratory distress syndrome	31.3	SFTPB CXCL8
3	chorioamnionitis	30.8	IL1RN FLT1 ELANE CXCL8
4	adult respiratory distress syndrome	30.7	SFTPB SELL SCGB1A1 IL1RN FGF7 ELANE
5	vascular disease	30.7	TIMP1 SOD1 RBP4 ELANE
6	pneumonia	30.6	SFTPB SCGB1A1 ELANE CXCL8
7	gastroesophageal reflux	30.5	IL1RN ELANE CXCL8
8	pulmonary edema	30.5	SCGB1A1 IL1RN FGF7 CXCL8
9	pulmonary fibrosis	30.4	TIMP1 FGF7 ELANE CXCL8
10	pre-eclampsia	30.4	SOD1 SELL FLT1 CXCL8
11	respiratory failure	30.4	SOD1 SFTPB SCGB1A1 RNASE3 FGF7 ELANE
12	extrinsic allergic alveolitis	30.2	SELL ELANE CXCL8
13	meconium aspiration syndrome	30.2	SFTPB SCGB1A1 CXCL8
14	bronchitis	30.2	RNASE3 ELANE CXCL8
15	interstitial lung disease	30.2	TIMP1 SFTPB IL1RN CXCL8
16	bronchiolitis obliterans	30.2	TIMP1 SCGB1A1 CXCL8
17	neonatal respiratory failure	30.2	SFTPB SCGB1A1 FGF10
18	pulmonary hemosiderosis	30.2	SFTPB IL1RN
19	allergic asthma	30.2	SCGB1A1 RNASE3 CXCL8
20	diaphragmatic hernia, congenital	30.1	SFTPB FGF7 FGF10
21	hypertension, essential	30.1	TXN TIMP1 SOD1 RBP4 FLT1 CXCL8
22	rhinitis	29.9	SCGB1A1 RNASE3 CXCL8
23	pulmonary disease, chronic obstructive	29.9	TIMP1 SFTPB SCGB1A1 RNASE3 ELANE CXCL8
24	exercise-induced bronchoconstriction	29.8	SCGB1A1 RNASE3 CXCL8
25	gastroenteritis	29.8	RNASE3 IL1RN CXCL8
26	bronchopneumonia	29.7	ELANE CXCL8
27	pulmonary emphysema	29.7	TIMP1 FGF7 ELANE CXCL8
28	otitis media	29.7	RNASE3 ELANE CXCL8
29	proteasome-associated autoinflammatory syndrome 1	29.6	SELL RNASE3 IL1RN ELANE CXCL8
30	asthma	29.6	TIMP1 SFTPB SELL SCGB1A1 RNASE3 ELANE
31	allergic rhinitis	29.6	SCGB1A1 RNASE3 CXCL8
32	lung disease	29.4	TXN TIMP1 SOD1 SFTPB SCGB1A1 RNASE3
33	cataract	29.2	TXN TIMP1 SOD1 IL1RN CXCL8
34	cystic fibrosis	28.8	TXN TIMP1 SFTPB RNASE3 RBP4 IL1RN
35	heart disease	28.7	SOD1 RBP4 IL1RN FLT1 ELANE CXCL8
36	interstitial lung disease 2	28.6	TIMP1 SFTPB SCGB1A1 IL1RN FGF7 FGF10
37	borderline personality disorder	11.4
38	pulmonary hypertension, neonatal	11.1
39	pulmonary hypertension	11.0
40	patent ductus arteriosus 1	10.9
41	personality disorder	10.8
42	respiratory distress syndrome in premature infants	10.8
43	exudative vitreoretinopathy 1	10.8
44	keratomalacia	10.8
45	enterocolitis	10.7
46	cerebral palsy	10.7
47	perinatal necrotizing enterocolitis	10.7
48	respiratory syncytial virus infectious disease	10.6
49	periventricular leukomalacia	10.6
50	cone-rod dystrophy 2	10.5

Graphical network of the top 20 diseases related to Bronchopulmonary Dysplasia:

Sources

Symptoms & Phenotypes for Bronchopulmonary Dysplasia

Human phenotypes related to Bronchopulmonary Dysplasia:

⁵⁸ ³⁰ (show all 22)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	emphysema ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002097
2	cough ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0012735
3	premature birth ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001622
4	respiratory distress ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002098
5	small for gestational age ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001518
6	chronic lung disease ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0006528
7	respiratory failure requiring assisted ventilation ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0004887
8	hyperoxemia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0012419
9	sleep disturbance ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002360
10	diaphragmatic paralysis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0006597
11	central apnea ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002871
12	exercise intolerance ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0003546
13	right ventricular hypertrophy ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001667
14	right ventricular failure ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001708
15	wheezing ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0030828
16	atelectasis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0100750
17	tracheobronchomalacia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002786
18	pulmonary sequestration ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0100632
19	dyspnea ⁵⁸		Very frequent (99-80%)
20	abnormal lung morphology ⁵⁸		Very frequent (99-80%)
21	abnormal respiratory system morphology ⁵⁸		Frequent (79-30%)
22	functional respiratory abnormality ⁵⁸		Frequent (79-30%)

MGI Mouse Phenotypes related to Bronchopulmonary Dysplasia:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10	ELANE FGF10 FGF7 FLT1 IL1RN RBP4
2	immune system	MP:0005387	9.85	ELANE FGF10 FGF7 FLT1 IL1RN RBP4
3	reproductive system	MP:0005389	9.56	FGF10 FGF7 FLT1 IL1RN RBP4 SELL
4	hematopoietic system	MP:0005397	9.32	ELANE FGF10 FGF7 FLT1 IL1RN RBP4

Sources

Drugs & Therapeutics for Bronchopulmonary Dysplasia

PubMed Health treatment related to Bronchopulmonary Dysplasia: ⁶³

If your doctor thinks you're going to give birth too early, he or she may give you injections of a corticosteroid medicine. The medicine can speed up surfactant production in your baby. Surfactant is a liquid that coats the inside of the lungs . It helps keep the lungs open so your infant can breathe in air once he or she is born. Corticosteroids also can help your baby's lungs , brain , and kidneys develop more quickly while he or she is in the womb . Premature babies who have very low birth weights also might be given corticosteroids within the first few days of birth. Doctors sometimes prescribe inhaled nitric oxide shortly after birth for babies who have very low birth weights. This treatment can help improve the babies' lung function. These preventive measures may help reduce infants' risk of respiratory distress syndrome (RDS), which can lead to BPD.

Drugs for Bronchopulmonary Dysplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 225)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Beractant

Approved

Phase 4

108778-82-1

Zinc cation

Approved, Experimental, Investigational

Phase 4

7440-66-6, 23713-49-7

32051

Zinc sulfate

Approved, Investigational

Phase 4

7733-02-0

Salbutamol

Approved, Vet_approved

Phase 4

18559-94-9

2083

Procaterol

Approved, Investigational

Phase 4

72332-33-3

688561 4916

Budesonide

Approved

Phase 4

51333-22-3

5281004 40000 63006

Azithromycin

Approved

Phase 4

83905-01-5

447043

Caffeine

Approved

Phase 4

58-08-2

2519

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

23431961

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

Dermatologic Agents

Phase 4

Bronchodilator Agents

Phase 4

Anti-Asthmatic Agents

Phase 4

Hormones

Phase 4

Pulmonary Surfactants

Phase 4

Hormone Antagonists

Phase 4

glucocorticoids

Phase 4

Respiratory System Agents

Phase 4

Anti-Inflammatory Agents

Phase 4

Neurotransmitter Agents

Phase 4

Anti-Bacterial Agents

Phase 4

Anti-Infective Agents

Phase 4

Phosphodiesterase Inhibitors

Phase 4

Central Nervous System Stimulants

Phase 4

Citrate

Phase 4

Caffeine citrate

Phase 4

Furosemide

Approved, Vet_approved

Phase 2, Phase 3

54-31-9

3440

Tocopherol

Approved, Investigational

Phase 3

1406-66-2

Spironolactone

Approved

Phase 2, Phase 3

1952-01-7, 52-01-7

5833

Chlorothiazide

Approved, Vet_approved

Phase 2, Phase 3

58-94-6

2720

Calfactant

Approved

Phase 3

183325-78-2

Prednisolone phosphate

Approved, Vet_approved

Phase 3

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 3

52-21-1

Prednisolone

Approved, Vet_approved

Phase 3

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 3

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 3

83-43-2

4159 6741

Palivizumab

Approved, Investigational

Phase 2, Phase 3

188039-54-5

Poractant alfa

Approved

Phase 3

129069-19-8

Hydrocortisone succinate

Approved

Phase 3

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 3

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 3

50-23-7

3640 5754

Ethanol

Approved

Phase 3

64-17-5

702

Benzyl alcohol

Approved

Phase 3

100-51-6

244

Clarithromycin

Approved

Phase 3

81103-11-9

84029

Amoxicillin

Approved, Vet_approved

Phase 3

26787-78-0

33613

Lidocaine

Approved, Vet_approved

Phase 3

137-58-6

3676

Nitric Oxide

Approved

Phase 2, Phase 3

10102-43-9

145068

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 3

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 3

50-02-2

3003 5743

DL-alpha-Tocopherol

Approved, Experimental, Investigational, Nutraceutical, Vet_approved

Phase 3

59-02-9, 10191-41-0

2116 14985

Interventional clinical trials:

(show top 50) (show all 264)

#	Name	Status	NCT ID	Phase	Drugs
1	Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome.	Unknown status	NCT03521063	Phase 4	Budesonide;Poractant Alfa;Saline
2	Routine Administration of Surfactant/Budesonide to Prevent BPD in VLBW With RDS-A Double Blind Study	Unknown status	NCT03275415	Phase 4	budesonide;Saline
3	Multicentre Randomised Controlled Trial of Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on Continuous Positive Airways Pressure	Unknown status	NCT02140580	Phase 4
4	Oral Zinc Supplementation Improving Growth and Reducing Morbidity on Very Low Birth Weight Infant	Unknown status	NCT04050488	Phase 4	Zinc Sulfate;Placebos
5	Early Administration of Surfactant in Spontaneous Breathing (TAKE CARE) Versus InSurE (Intubation, Surfactant, Extubation) : A Pilot Study	Unknown status	NCT01329432	Phase 4
6	Prevention of Chronic Lung Disease (CLD) in Preterm Infants -A New Therapeutic Regimen	Unknown status	NCT00883532	Phase 4	budesonide;surfactant and air (placebo)
7	Albuterol Dose-Response on Pulmonary Function Testing in Preterm Infants at Risk of Bronchopulmonary Dysplasia	Completed	NCT02447250	Phase 4	Varied albuterol dose response
8	The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia (BPD).	Completed	NCT00926276	Phase 4
9	Exogenous Surfactant in Very Preterm Neonates Presenting With Severe Respiratory Distress in Prevention of Bronchopulmonary Dysplasia	Completed	NCT01039285	Phase 4	Curosurf
10	Randomized Clinical Trial: Use of Azithromycin to Prevent Lung Damage in Preterm Newborns Under Mechanical Ventilation	Completed	NCT03485703	Phase 4	Azithromycin;Placebo
11	The Efect of Azithromicyn on Bronchopulmonary Displasia in Extremely Preterm and Very Preterm Infant	Recruiting	NCT05311228	Phase 4	Azithromycin Powder
12	Intra-tracheal Instillation of Budesonide Along With Surfactant in Preterm Infants to Prevent Chronic Lung Disease	Recruiting	NCT05364385	Phase 4	Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL);Infants in the control group (S/P group) receive placebo (Normal saline 1mL)
13	The Caffeine Therapy in the Fetal to Neonatal Transition in Preterms	Recruiting	NCT05454332	Phase 4	Early Caffeine administration
14	A Randomized, Placebo-controlled Trial of Early Caffeine in Preterm Neonates	Active, not recruiting	NCT03086473	Phase 4	Caffeine Citrate;Placebo (Normal Saline)
15	Rate of Bronchopulmonary Dysplasia in Preterms Neonates Less Than 29 Weeks' Gestational Age and / or With Birth Weight Less Than 1000 g: a Double Blind Randomized Controlled Multicenter Trial Comparing SMOFlipid and Medialipide	Withdrawn	NCT02853253	Phase 4
16	Prophylaxis of Bronchopulmonary Dysplasia With Clarithromycin	Unknown status	NCT01652118	Phase 3	clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia;Saline
17	Effects of Fat-soluble Vitamins Supplementation in Early Life on Common Complications and Neural Development in Very Low Birth Weight Infants	Unknown status	NCT03876704	Phase 3	High dose of fat-Soluble Vitamin;Conventional dose of fat-Soluble Vitamin
18	Effect of Cysteine Supplementation on Glutathione Production in Critically Ill Neonates	Unknown status	NCT00254176	Phase 2, Phase 3
19	Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease	Unknown status	NCT01721655	Phase 2, Phase 3	Spironolactone;Placebo
20	Efficacy and Safety of NIPPV to Increase Survival Without Bronchopulmonary Dysplasia in Extremely Low Birth Weight Infants	Completed	NCT00433212	Phase 3
21	Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia: A Study in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide	Completed	NCT01022580	Phase 3	Infasurf surfactant (ONY, Inc.);Sham (No Treatment)
22	Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia	Completed	NCT01035190	Phase 3	Budesonide
23	Phase III Randomized, Double-Blind Study of Dexamethasone Vs Dexamethasone/Methylprednisolone Vs Placebo for Bronchopulmonary Dysplasia	Completed	NCT00004785	Phase 3	dexamethasone;methylprednisolone
24	Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth	Completed	NCT00931632	Phase 3	Inhaled Nitric Oxide;Placebo
25	Inhaled Nitric Oxide to Prevent and Treat Bronchopulmonary Dysplasia in Preterm Infants	Completed	NCT01503801	Phase 2, Phase 3	Nitric Oxide
26	Inhaled NO for the Prevention of Chronic Lung Disease	Completed	NCT00006401	Phase 3	iNO
27	A Prospective, Multicenter, Open-label, Non-comparative Study of Safety and Efficacy of Synagis in Children at High Risk of Severe Respiratory Syncytial Virus Infection in the Russian Federation	Completed	NCT01006629	Phase 2, Phase 3
28	Randomized Clinical Trial of Dexamethasone Therapy in Very-Low-Birth-Weight Infants at Risk for Chronic Lung Disease (CLD)	Completed	NCT00011362	Phase 3	Dexamethasone Early;Dexamethasone Late
29	Inhaled NO in Prevention of Chronic Lung Disease	Completed	NCT00000548	Phase 3
30	A Randomized, Controlled Trial of Synchronized Nasal Intermittent Positive Pressure Ventilation Versus Nasal Continuous Positive Airway Pressure Using the Infant Flow Advance to Facilitate Successful Extubation in Premature Infants.	Completed	NCT00188968	Phase 3
31	High Frequency Ventilation in Premature Infants (HIFI)	Completed	NCT00000567	Phase 3
32	Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide	Completed	NCT00569530	Phase 3	Infasurf (ONY Inc.);Sham
33	Randomized Comparison of Two Models of Post-NICU Care for Preterm Infants With Neonatal Chronic Lung Disease	Completed	NCT00314431	Phase 3
34	Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants	Completed	NCT00233324	Phase 3	Surfactant;Supplemental oxygen with target saturation of 85 to 89%;Supplemental oxygen with target saturation of 91 to 95%
35	Inhaled Beclomethasone to Prevent Chronic Lung Disease	Completed	NCT00000576	Phase 3	beclomethasone
36	Early Vitamin D Supplementation for Prevention of Respiratory Morbidity in Extremely Preterm Infants: A Randomized Clinical Trial	Completed	NCT01600430	Phase 2, Phase 3
37	Early Prevention of Broncho-pulmonary Dysplasia and Neonatal Mortality in Very Preterm Infants Using Low Dose of Hydrocortisone: a Randomized Controlled Trial	Completed	NCT00623740	Phase 3	hydrocortisone;placebo
38	Efficacy and Safety of Exosurf Neonatal and Survanta for the Treatment of Respiratory Distress Syndrome	Completed	NCT01203358	Phase 2, Phase 3	Exosurf;Survanta
39	Effect of Autologous Cord Blood Mononuclear Cells for Prevention of Bronchopulmonary Dysplasia in Extremely Preterm Neonates: a Placebo-controlled Randomized Multicenter Trial	Recruiting	NCT04440670	Phase 3
40	Randomized Controlled Trial of Budesonide + Surfactant Versus Surfactant Alone in Extremely Preterm Infants ("The Budesonide in Babies (BiB) Trial")	Recruiting	NCT04545866	Phase 3	budesonide (Pulmicort nebulizing suspension).;surfactant (poractant alfa;Curosurf)
41	Maternal Omega-3 Supplementation to Reduce BronchopulmonarY Dysplasia in Very Preterm Infants (MOBYDIck Trial)	Active, not recruiting	NCT02371460	Phase 3
42	A Randomized Controlled Trial of the Effect of Hydrocortisone on Survival Without Bronchopulmonary Dysplasia and on Neurodevelopmental Outcomes at 22 - 26 Months of Age in Intubated Infants < 30 Weeks Gestation Age	Active, not recruiting	NCT01353313	Phase 3	Hydrocortisone;Placebo
43	Transfusion of Prematures (TOP) Trial: Does a Liberal Red Blood Cell Transfusion Strategy Improve Neurologically-Intact Survival of Extremely-Low-Birth-Weight Infants as Compared to a Restrictive Strategy?	Active, not recruiting	NCT01702805	Phase 3
44	Inhaled Nitric Oxide and Neuroprotection in Premature Infants	Active, not recruiting	NCT00515281	Phase 2, Phase 3	inhaled nitric oxide;oxygen
45	A Randomized Controlled Trial of Mid and Standard Frequency Ventilation in Infants With Respiratory Distress Syndrome	Active, not recruiting	NCT03231735	Phase 2, Phase 3
46	Efficacy and Safety of the Intratracheal Administration of Budesonide With Porcine Pulmonary Surfactant in Very Preterm Infants to Prevent Bronchopulmonary Dysplasia: Randomized Clinical Trial (BuS Trial)	Not yet recruiting	NCT04862377	Phase 3	Poractant Alfa Intratracheal Suspension [Curosurf];Budesonide 0.5 MG/ML
47	Effect of Autologous Cord Blood Mononuclear Cells for Treatment of Bronchopulmonary Dysplasia in Extremely Preterm Neonates: a Non-Randomized Case-Control Trial Study	Not yet recruiting	NCT05071638	Phase 3
48	Treatment of Classic Mid-trimester Preterm Premature Rupture of Membranes (PPROM) With Oligo/Anhydramnion Between 22/0-26/0 Week of Gestation by Means of Continuous Amnioinfusion: a Multicenter Prospectiv Randomized Trial	Not yet recruiting	NCT04696003	Phase 3
49	Management of Hyponatremia in Preterm Infants on Diuretics	Terminated	NCT00156572	Phase 3
50	Randomized Trial of Minimal Ventilator Support and Early Corticosteroid Therapy to Increase Survival Without Chronic Lung Disease in Extremely-Low-Birth-Weight Infants	Terminated	NCT00005777	Phase 3	Dexamethasone;Placebo

Search NIH Clinical Center for Bronchopulmonary Dysplasia

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Bronchopulmonary Dysplasia cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Bronchopulmonary Dysplasia:

PNEUMOSTEM, cord blood-derived mesenchymal stem cells for bronchopulmonary dysplasia

Sources

Genetic Tests for Bronchopulmonary Dysplasia

Sources

Anatomical Context for Bronchopulmonary Dysplasia

Organs/tissues related to Bronchopulmonary Dysplasia:

MalaCards : Lung, Bone Marrow, Whole Blood, Brain, Heart, Fetal Lung, Skin

Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Bronchopulmonary Dysplasia:

#	Tissue Anatomical CompartmentCell	Relevance
1	Lung Pulmonary Capillary Plexus	Affected by disease
2	Lung Alveoli Alveolar Epithelial Type 1 Cells	Affected by disease, potential therapeutic candidate
3	Lung Alveoli Alveolar Epithelial Type 2 Cells	Affected by disease, potential therapeutic candidate

Sources

Publications for Bronchopulmonary Dysplasia

Articles related to Bronchopulmonary Dysplasia:

(show top 50) (show all 8331)

#	Title	Authors	PMID	Year
1	Cord blood Clara cell protein CC16 predicts the development of bronchopulmonary dysplasia. ⁵³ ⁶²	Schrama AJ...Walther FJ	18521627	2008
2	Clara cell secretory protein (CC16) as a peripheral blood biomarker of lung injury in ventilated preterm neonates. ⁵³ ⁶²	Sarafidis K...Drossou V	18521628	2008
3	Gastrin-releasing peptide, immune responses, and lung disease. ⁵³ ⁶²	Degan S...Sunday ME	19076373	2008
4	FGF-10 is decreased in bronchopulmonary dysplasia and suppressed by Toll-like receptor activation. ⁵³ ⁶²	Benjamin JT...Prince LS	17071719	2007
5	Selectin polymorphisms and perinatal morbidity in low-birthweight infants. ⁵³ ⁶²	Derzbach L...Rigo J	16982492	2006
6	Lower parathyroid hormone-related protein content of tracheal aspirates in very low birth weight infants who develop bronchopulmonary dysplasia. ⁵³ ⁶²	Rehan VK...Torday JS	16864707	2006
7	Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. ⁵³ ⁶²	Ohlsson A...Aher SM	16856062	2006
8	The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome. ⁵³ ⁶²	Levine CR...Davis JM	15774846	2005
9	Erythrocyte Cu/Zn superoxide dismutase activity in preterm infants with and without bronchopulmonary dysplasia. ⁵³ ⁶²	Fu RH...Chou YH	15767740	2005
10	Distribution of antioxidant enzymes in developing human lung, respiratory distress syndrome, and bronchopulmonary dysplasia. ⁵³ ⁶²	Kaarteenaho-Wiik R...Kinnula VL	15314090	2004
11	Neutrophil and monocyte adhesion molecules in bronchopulmonary dysplasia, and effects of corticosteroids. ⁵³ ⁶²	Ballabh P...Cunningham-Rundles S	14711863	2004
12	Interleukin-10 inhibits proinflammatory chemokine release by neutrophils of the newborn without suppression of nuclear factor-kappa B. ⁵³ ⁶²	Tryzmel J...Davidson D	12788980	2003
13	Soluble E-selectin, soluble L-selectin and soluble ICAM-1 in bronchopulmonary dysplasia, and changes with dexamethasone. ⁵³ ⁶²	Ballabh P...Cunningham-Rundles S	12612222	2003
14	Roles for insulin-like growth factor I and transforming growth factor-beta in fibrotic lung disease. ⁵³ ⁶²	Krein PM...Winston BW	12475802	2002
15	Secretoglobins SCGB3A1 and SCGB3A2 define secretory cell subsets in mouse and human airways. ⁵³ ⁶²	Reynolds SD...Stripp BR	12406855	2002
16	High concentrations of keratinocyte growth factor in airways of premature infants predicted absence of bronchopulmonary dysplasia. ⁵³ ⁶²	Danan C...Delacourt C	12016100	2002
17	Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. ⁵³ ⁶²	Bhatt AJ...Maniscalco WM	11734454	2001
18	Monocyte chemoattractant protein-1 and interleukin-8 are increased in bronchopulmonary dysplasia: relation to isolation of Ureaplasma urealyticum. ⁵³ ⁶²	Baier RJ...Kruger TE	11478413	2001
19	Superoxide dismutase for preventing chronic lung disease in mechanically ventilated preterm infants. ⁵³ ⁶²	Suresh GK...Soll RF	11279743	2001
20	Effects of early inhaled beclomethasone therapy on tracheal aspirate inflammatory mediators IL-8 and IL-1ra in ventilated preterm infants at risk for bronchopulmonary dysplasia. ⁵³ ⁶²	Gupta GK...Frantz ID	11015126	2000
21	An alternatively spliced surfactant protein B mRNA in normal human lung: disease implication. ⁵³ ⁶²	Lin Z...Floros J	10493923	1999
22	Hyperoxia induces thioredoxin and thioredoxin reductase gene expression in lungs of premature baboons with respiratory distress and bronchopulmonary dysplasia. ⁵³ ⁶²	Das KC...White CW	10424622	1999
23	Effect of oxygen on lung superoxide dismutase activities in premature baboons with bronchopulmonary dysplasia. ⁵³ ⁶²	Morton RL...White CW	9887057	1999
24	Elevated interleukin-8 concentrations in amniotic fluid of mothers whose neonates subsequently develop bronchopulmonary dysplasia. ⁵³ ⁶²	Ghezzi F...Mazor M	9605441	1998
25	L-selectin expression on polymorphonuclear leukocytes and monocytes in premature infants: reduced expression after dexamethasone treatment for bronchopulmonary dysplasia. ⁵³ ⁶²	Waisman D...Bondy GP	9470000	1998
26	Cromolyn sodium prophylaxis inhibits pulmonary proinflammatory cytokines in infants at high risk for bronchopulmonary dysplasia. ⁵³ ⁶²	Viscardi RM...Palmer TW	9372670	1997
27	Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia. ⁵³ ⁶²	Munshi UK...Parton LA	9407566	1997
28	Airway lesions and superoxide dismutase (SOD) distribution in bronchopulmonary dysplasia (BPD). ⁵³ ⁶²	Ohbayashi C...Itoh H	9642974	1997
29	Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. ⁵³ ⁶²	Yoon BH...Kim BI	9369827	1997
30	Eosinophil cationic protein in tracheal aspirates of preterm infants with bronchopulmonary dysplasia. ⁵³ ⁶²	Raghavender B...Smith JB	9202617	1997
31	Altered platelet-activating factor levels and acetylhydrolase activities are associated with increasing severity of bronchopulmonary dysplasia. ⁵³ ⁶²	Gaylord MS...Snyder F	8853062	1996
32	Elevated cytokine levels in tracheobronchial aspirate fluids from ventilator treated neonates with bronchopulmonary dysplasia. ⁵³ ⁶²	Tullus K...Brauner A	8775225	1996
33	Use of the intramuscular relative-dose-response test to predict bronchopulmonary dysplasia in premature infants. ⁵³ ⁶²	Zachman RD...Pi JT	8604659	1996
34	Secretory leukocyte protease inhibitor and lung inflammation in developing bronchopulmonary dysplasia. ⁵³ ⁶²	Watterberg KL...Murphy S	7913723	1994
35	Proteinase-antiproteinase balance in tracheal aspirates from neonates. ⁵³ ⁶²	Sluis KB...Winterbourn CC	7909297	1994
36	Pulmonary endocrine cells in infancy and childhood. ⁵³ ⁶²	Nakatani Y	2014192	1991
37	Plasma retinol-binding protein response to vitamin A administration in infants susceptible to bronchopulmonary dysplasia. ⁵³ ⁶²	Shenai JP...Chytil F	2108233	1990
38	Clinical characteristics and outcomes in neonates with perinatal acute respiratory distress syndrome in China: A national, multicentre, cross-sectional study. ⁶²	Chen L...Chinese Neonatal ARDS (ChiNARDS) study group	36386029	2023
39	How lung injury and therapeutic oxygen could alter white matter development. ⁶²	Dettman RW...Dizon MLV	33687103	2022
40	Lung ultrasound assessment of pulmonary edema in neonates with chronic lung disease before and after diuretic therapy. ⁶²	Kasniya G...Kurepa D	36174499	2022
41	Understanding the role of placental pathophysiology in the development of bronchopulmonary dysplasia. ⁶²	Parsons A...Taglauer ES	36219136	2022
42	Maternal Ureaplasma exposure during pregnancy and the risk of preterm birth and BPD: a meta-analysis. ⁶²	Xu YP...Shi LP	35277749	2022
43	Clinical Significance of Early Pulmonary Hypertension in Preterm Infants. ⁶²	Arjaans S...Berger RMF	35934129	2022
44	Screening Echocardiography Identifies Risk Factors for Pulmonary Hypertension at Discharge in Premature Infants with Bronchopulmonary Dysplasia. ⁶²	Madden BA...McCulloch MA	35488130	2022
45	Safety of sildenafil in premature infants at risk of bronchopulmonary dysplasia: Rationale and methods of a phase II randomized trial. ⁶²	Lang JE...Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee	36345347	2022
46	Respiratory problems in preterm infants with pulmonary hemorrhage. ⁶²	Bozkaya A...Doganer A	34384331	2022
47	Low flow nasal cannula requirement among preterm infants: predictors and description of clinical course. ⁶²	Daigneault J...Rhein L	36045221	2022
48	Effects of prophylactic indomethacin on morbidity and mortality in infants <25 weeks' gestation: a protocol driven intention to treat analysis. ⁶²	Clyman RI...Hills NK	36310242	2022
49	Dual medication therapy (acetaminophen and ibuprofen) for the management of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. ⁶²	Shah SD...Hudak ML	36008521	2022
50	Adverse perinatal outcomes in fetuses with severe late-onset fetal growth restriction. ⁶²	Bahia MLR...Sa RAM	34702116	2022

Sources

Genes for Bronchopulmonary Dysplasia

Genes related to Bronchopulmonary Dysplasia (0 elite genes):

(show all 14)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	SFTPB	Surfactant Protein B	Protein Coding	17.53	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10493923
2	SCGB1A1	Secretoglobin Family 1A Member 1	Protein Coding	15.59	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12406855 18521627 15774846 (more) 18521628
3	SOD1	Superoxide Dismutase 1	Protein Coding	13.46	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15767740 11279743 15314090 (more) 9887057 9642974
4	RBP4	Retinol Binding Protein 4	Protein Coding	13.37	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	2108233 8604659
5	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	13.34	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9369827 9605441 12788980 (more) 11478413 11015126 9407566 8775225
6	SELL	Selectin L	Protein Coding	12.65	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9470000 14711863 16982492 (more) 12612222
7	ELANE	Elastase, Neutrophil Expressed	Protein Coding	12.44	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7909297 7913723
8	IL1RN	Interleukin 1 Receptor Antagonist	Protein Coding	12.36	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11015126 8775225 9372670
9	FGF7	Fibroblast Growth Factor 7	Protein Coding	12.35	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12475802 12016100
10	TIMP1	TIMP Metallopeptidase Inhibitor 1	Protein Coding	11.77	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16856062
11	FGF10	Fibroblast Growth Factor 10	Protein Coding	11.64	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17071719
12	FLT1	Fms Related Receptor Tyrosine Kinase 1	Protein Coding	10.26	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11734454
13	TXN	Thioredoxin	Protein Coding	10.05	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10424622 15314090
14	RNASE3	Ribonuclease A Family Member 3	Protein Coding	10.01	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9202617

Sources

Variations for Bronchopulmonary Dysplasia

ClinVar genetic disease variations for Bronchopulmonary Dysplasia:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	ITGA3	NM_002204.4(ITGA3):c.1766G>C (p.Arg589Pro)	SNV	Uncertain Significance	1339481		GRCh37: 17:48153781-48153781 GRCh38: 17:50076417-50076417

Sources

Expression for Bronchopulmonary Dysplasia

Search GEO for disease gene expression data for Bronchopulmonary Dysplasia.

Sources

Pathways for Bronchopulmonary Dysplasia

Pathways related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.56	TXN TIMP1 SOD1 SELL RNASE3 IL1RN
2	NF-KappaB Family Pathway ⁶⁴ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁴	12.24	TIMP1 FLT1 FGF7 FGF10
3	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.16	TIMP1 FLT1 FGF7 FGF10 CXCL8
4	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	11.95	TIMP1 FLT1 FGF7 FGF10
5	Lung fibrosis ⁷⁴	10.93	TIMP1 FGF7 CXCL8
6	Interleukin-10 signaling ⁶⁶	10.47	TIMP1 IL1RN CXCL8
7	G-protein signaling_Rap2B regulation pathway ²²	10.46	TIMP1 FLT1 FGF7 FGF10 CXCL8

Sources

GO Terms for Bronchopulmonary Dysplasia

Cellular components related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	10.03	CXCL8 ELANE FGF10 FGF7 FLT1 IL1RN
2	extracellular region	GO:0005576	9.68	TXN TIMP1 SOD1 SFTPB SCGB1A1 RNASE3

Biological processes related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	lung development	GO:0030324	9.85	RBP4 FGF7 FGF10
2	positive regulation of keratinocyte proliferation	GO:0010838	9.78	FGF7 FGF10
3	induction of positive chemotaxis	GO:0050930	9.73	FGF10 CXCL8
4	chemotaxis	GO:0006935	9.73	RNASE3 FLT1 FGF10 CXCL8
5	response to organic substance	GO:0010033	9.72	SCGB1A1 SOD1 TIMP1
6	positive regulation of keratinocyte migration	GO:0051549	9.71	FGF7 FGF10
7	branching involved in salivary gland morphogenesis	GO:0060445	9.54	FGF7 FGF10
8	secretion by lung epithelial cell involved in lung growth	GO:0061033	9.46	FGF7 FGF10
9	regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling	GO:0060665	9.26	FGF7 FGF10
10	female genitalia morphogenesis	GO:0048807	8.92	RBP4 FGF10